NCT02013960 is a NA clinical trial of Cytotec in Other Abortion, sponsored by Rambam Health Care Campus.

Who is sponsoring NCT02013960?

NCT02013960 is sponsored by Rambam Health Care Campus.

What drugs are being tested in NCT02013960?

Interventions in NCT02013960: Cytotec.

What condition does NCT02013960 study?

NCT02013960 studies Other Abortion.

Is NCT02013960 still recruiting?

NCT02013960 is currently status unknown. Last updated 11 December 2013.

Last reviewed 2013-12-11 · How we verify

NCT02013960

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparison Between Sublingual Misoprostol vs. Sublingual Misoprostol and Laminaria For Second Trimester Termination of Pregnancy

Status unknown NA Last updated 11 December 2013

What this trial tests

NA trial testing Cytotec in Other Abortion in 100 participants. Status unknown.

Timeline

1 January 2014

Primary endpoint
1 December 2014

1 December 2014

Quick facts

Lead sponsor	Rambam Health Care Campus
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	health services research
Enrollment	100
Start date	1 January 2014
Primary completion	1 December 2014
Estimated completion	1 December 2014
Sites	1 location across Israel

Drugs / interventions tested

Cytotec (Misoprostol) — full drug profile →

Conditions studied

Other Abortion — all drugs for Other Abortion →

Sponsor

Rambam Health Care Campus — full company profile →

Who can join

Adults 18 to 50, female only, with Other Abortion. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Duration of time until pregnancy termination
Time frame: Average time 12 hours
From the time of receiving the treatment until complete abortion

Sponsor's own description

1. Comparison between the duration of time from the beginning of cervical preparation until abortion, between sublingual misoprostol and the combination of sublingual misoprostol with laminaria for second trimester medical termination of pregnancy (TOP). 2. Comparison between the adverse event rate following Sublingual misoprostol only vs. Sublingual misoprostol and laminaria given for pregnancy termination. 3. Comparison between the levels of satisfaction rate of women who underwent pregnancy termination with sublingual misoprostol vs. sublingual misoprostol with laminaria.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Cervical preparation for dilation and evacuation at 12 to 24 weeks gestation.
Tufa TH, Stewart F, Meckstroth K, Diedrich JT, et al · · 2025 · PMID 40028776 · DOI 10.1002/14651858.cd007310.pub3

Verify or expand the search:

Other trials of Cytotec

Trials testing the same drug.

NCT04004845 — Labor Protocol Study · terminated

Other Rambam Health Care Campus trials

Trials by the same sponsor.

NCT07384013 — Study Protocol: Impact of Metamizole (Optalgin®) on Anti-Xa Concentrations in Oncology Patients Receiving DOACs · NA · recruiting
NCT06688253 — Intravenous Human IgG1 Fc Fragment (Efgartigimod) in Myasthenic Crisis · Phase 4 · not yet recruiting
NCT06235749 — Administration Of Calcium Gluconate for The Reduction of Blood Loss During Elective Cesarean Delivery · NA · recruiting
NCT06622902 — Influence of Flow Rate Change on CO2 Levels During High Flow Nasal Ventilation (HFNV) in Preterm Infants. · NA · recruiting
NCT05922111 — Cervical Ripening Balloon for 12 Hours vs. 1 Hour. · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02013960 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Rambam Health Care Campus
Last refreshed: 11 December 2013

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02013960.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing